Developer docs
API playgroundTry for free, no card

Search company profiles

PLL Therapeutics

Full company profile

uuid002p8un

Namestring
PLL Therapeutics
Legal namestring
PLL THERAPEUTICS
Company typeenum
Private
Founded yearint
2019
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVillenave-d'ornon, France
HQ citystring
Villenave-d'ornon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical drug development, ALS therapy research, polypeptide drug delivery, blood biomarker diagnostics, gut-brain axis therapeutics
Industry2 codes
PRIMARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
SECONDARYHLAAAMAB
Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
SIC code2 codes
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Neurology Biopharmaceuticals (ALS Therapeutics)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Development and Licensing
TypeOne Time License
Description

As a clinical-stage biopharmaceutical company, PLL Therapeutics is developing PLL001 for ALS treatment. Revenue will likely come from drug approval and commercialization, with potential for licensing agreements, partnerships with larger pharmaceutical companies, or direct commercialization upon regulatory approval.

pll-therapeutics.com
2Diagnostic Services
TypeSubscription Recurring
Description

The company offers early-stage and companion diagnostics services using its blood biomarker test. This represents a potential revenue stream from diagnostic testing services.

pll-therapeutics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

PLL Therapeutics develops a proprietary Poly-L-Lysine (PLL) polypeptide delivery platform designed to transport therapeutic molecules to gut cells and across the blood–brain barrier. Its lead product candidate, PLL001, is a first-in-class investigational therapy for Amyotrophic Lateral Sclerosis (ALS) targeting the gut–brain axis. The company also offers an early-stage, non-invasive blood biomarker diagnostic test for ALS with reported 92% sensitivity.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase I trial completed with no Serious Adverse Events (SAE) reported and no Treatment Emergent Adverse Events (TEAEs) resulting in study discontinuation
+3 more records
Product overview1 text field

PLL Therapeutics operates as a biopharmaceutical company with a platform-plus-products model. The core offering is the Polypeptide Delivery Platform, which uses patented Poly-L-Lysine technology to transport active pharmaceutical ingredients to target tissues. The primary product in development is PLL001, a poly-targeted drug therapy for ALS that combines multiple APIs (DP1 and DP2) to restore microbiome function and intestinal permeability. Supporting the therapeutic approach is an early-stage diagnostic service utilizing blood biomarkers for ALS detection. All offerings center on the company's gut-brain axis hypothesis for treating neurodegenerative and autoimmune diseases.

Product and service4 records
1PLL001
CategoryInvestigational ALS therapy (polypeptide)
Description

PLL001 is a first-in-class investigational therapy for Amyotrophic Lateral Sclerosis (ALS) that uses the Poly-L-Lysine delivery platform to target the gut–brain axis, aiming to restore intestinal and blood–brain barrier integrity. It is being developed for ALS patients and pharmaceutical licensing partners.

2Poly-L-Lysine (PLL) Polypeptide Delivery Platform
CategoryDrug delivery technology platform
Description

Proprietary Poly-L-Lysine (PLL) polypeptide technology platform that enables targeted transport of therapeutic molecules to gut cells and across the blood–brain barrier. It underpins PLL001 and is positioned for licensing to pharmaceutical partners.

3ALS Blood Biomarker Diagnostic Test
CategoryCompanion diagnostic / blood biomarker test
Description

Non-invasive companion diagnostic blood test for ALS with reported 92% sensitivity, intended to support early detection and patient stratification in clinical and commercial settings.

4DP1 and DP2 (Polypeptide Building Blocks)
CategoryPlatform component / building block
Description

DP1 and DP2 are the proprietary polypeptide building blocks of the Poly-L-Lysine delivery platform, commercially protected and used to construct PLL Therapeutics' therapeutic candidates.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Australian Contract Research Organization (CRO) collaborating with PLL Therapeutics on the Phase I/II clinical trial for PLL001 in ALS patients. Alithia Lifesciences provides clinical research expertise and site management for the multi-stage study conducted across Australian sites.

2Copexis
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Swiss consultancy firm providing strategic and operational support for PLL Therapeutics' clinical development program. Partnership facilitates international trial coordination and regulatory affairs expertise.

pll-therapeutics.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Largest public hospital in Melbourne, Australia, serving as the lead clinical site for the Phase I/II ALS trial. Enrolled the first patient in April 2025 and conducted Phase I with 12 patients under Prof. Susan Mathers as lead investigator.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Major Australian hospital network participating as a clinical trial site for PLL Therapeutics' Phase I/II ALS study conducted across multiple sites.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Australian healthcare provider participating as a clinical trial site for PLL Therapeutics' Phase I/II ALS study.

6Wesley Research Institute
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Australian research institute participating as a clinical trial site for PLL Therapeutics' Phase I/II ALS study.

pll-therapeutics.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

New Zealand clinical research organization serving as the single site for Phase II trial enrollment in New Zealand. David Tudor Phillips appointed as director of PLL Tx New Zealand to oversee operations.

8Dr. Philippe Corcia
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Preeminent ALS researcher appointed to scientific board in June 2025. Head of ALS Reference Centre since 2005, Professor of Neurology since 2010. Presides over French ALS motor neuron study group and FILSLAN network coordination center. Has co-authored over 300 publications on ALS and participates in MinE and PRECISION clinical studies.

pll-therapeutics.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PLL Therapeutics

Neurology Biopharmaceuticals (ALS Therapeutics)pll-therapeutics.com

PLL Therapeutics firmographics

Firmographics
Name
PLL Therapeutics
Legal name
PLL THERAPEUTICS
Website
https://pll-therapeutics.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

PLL Therapeutics industry classification

Industry
Product category
Neurology Biopharmaceuticals (ALS Therapeutics)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
SIC
Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
SECONDARYHLAAAMAB
Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Biopharmaceutical drug development
  • ALS therapy research
  • Polypeptide drug delivery
  • Blood biomarker diagnostics
  • Gut-brain axis therapeutics

Where PLL Therapeutics is headquartered

Location

Headquarters

HQ city
Villenave-d'ornon
HQ country
France
HQ region
Europe

Offices4 records

Markets served

PLL Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Development and Licensing: As a clinical-stage biopharmaceutical company, PLL Therapeutics is developing PLL001 for ALS treatment. Revenue will likely come from drug approval and commercialization, with potential for licensing agreements, partnerships with larger pharmaceutical companies, or direct commercialization upon regulatory approval.
  2. Diagnostic Services: The company offers early-stage and companion diagnostics services using its blood biomarker test. This represents a potential revenue stream from diagnostic testing services.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

PLL Therapeutics product offering

Product offering

Core offering

PLL Therapeutics develops a proprietary Poly-L-Lysine (PLL) polypeptide delivery platform designed to transport therapeutic molecules to gut cells and across the blood–brain barrier. Its lead product candidate, PLL001, is a first-in-class investigational therapy for Amyotrophic Lateral Sclerosis (ALS) targeting the gut–brain axis. The company also offers an early-stage, non-invasive blood biomarker diagnostic test for ALS with reported 92% sensitivity.

Product overview

PLL Therapeutics operates as a biopharmaceutical company with a platform-plus-products model. The core offering is the Polypeptide Delivery Platform, which uses patented Poly-L-Lysine technology to transport active pharmaceutical ingredients to target tissues. The primary product in development is PLL001, a poly-targeted drug therapy for ALS that combines multiple APIs (DP1 and DP2) to restore microbiome function and intestinal permeability. Supporting the therapeutic approach is an early-stage diagnostic service utilizing blood biomarkers for ALS detection. All offerings center on the company's gut-brain axis hypothesis for treating neurodegenerative and autoimmune diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • PLL001 PLL001 is a first-in-class investigational therapy for Amyotrophic Lateral Sclerosis (ALS) that uses the Poly-L-Lysine delivery platform to target the gut–brain axis, aiming to restore intestinal and blood–brain barrier integrity. It is being developed for ALS patients and pharmaceutical licensing partners.
  • Poly-L-Lysine (PLL) Polypeptide Delivery Platform Proprietary Poly-L-Lysine (PLL) polypeptide technology platform that enables targeted transport of therapeutic molecules to gut cells and across the blood–brain barrier. It underpins PLL001 and is positioned for licensing to pharmaceutical partners.
  • ALS Blood Biomarker Diagnostic Test Non-invasive companion diagnostic blood test for ALS with reported 92% sensitivity, intended to support early detection and patient stratification in clinical and commercial settings.
  • DP1 and DP2 (Polypeptide Building Blocks) DP1 and DP2 are the proprietary polypeptide building blocks of the Poly-L-Lysine delivery platform, commercially protected and used to construct PLL Therapeutics' therapeutic candidates.

Quantifiable outcome

  • Phase I trial completed with no Serious Adverse Events (SAE) reported and no Treatment Emergent Adverse Events (TEAEs) resulting in study discontinuation
  • +3 more outcomes

Companies that use PLL Therapeutics

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

PLL Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

PLL Therapeutics partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core.

  • Alithia LifesciencescoreStrategic or Co-development PartnerAustralian Contract Research Organization (CRO) collaborating with PLL Therapeutics on the Phase I/II clinical trial for PLL001 in ALS patients. Alithia Lifesciences provides clinical research expertise and site management for the multi-stage study conducted across Australian sites.
  • CopexiscoreStrategic or Co-development PartnerSwiss consultancy firm providing strategic and operational support for PLL Therapeutics' clinical development program. Partnership facilitates international trial coordination and regulatory affairs expertise.
  • Monash HealthcoreStrategic or Co-development PartnerLargest public hospital in Melbourne, Australia, serving as the lead clinical site for the Phase I/II ALS trial. Enrolled the first patient in April 2025 and conducted Phase I with 12 patients under Prof. Susan Mathers as lead investigator.
  • Alfred HealthcoreStrategic or Co-development PartnerMajor Australian hospital network participating as a clinical trial site for PLL Therapeutics' Phase I/II ALS study conducted across multiple sites.
  • Calvary Health CarecoreStrategic or Co-development PartnerAustralian healthcare provider participating as a clinical trial site for PLL Therapeutics' Phase I/II ALS study.
  • Wesley Research InstitutecoreStrategic or Co-development PartnerAustralian research institute participating as a clinical trial site for PLL Therapeutics' Phase I/II ALS study.
  • Pacific Clinical Research Network (PCRN)coreStrategic or Co-development PartnerNew Zealand clinical research organization serving as the single site for Phase II trial enrollment in New Zealand. David Tudor Phillips appointed as director of PLL Tx New Zealand to oversee operations.
  • Dr. Philippe CorciacoreStrategic or Co-development PartnerPreeminent ALS researcher appointed to scientific board in June 2025. Head of ALS Reference Centre since 2005, Professor of Neurology since 2010. Presides over French ALS motor neuron study group and FILSLAN network coordination center. Has co-authored over 300 publications on ALS and participates in MinE and PRECISION clinical studies.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

PLL Therapeutics competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

PLL Therapeutics social profiles

Digital presence

PLL Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PLL Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

PLL Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

PLL Therapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PLL Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PLL Therapeutics

What does PLL Therapeutics do?

PLL Therapeutics develops a proprietary Poly-L-Lysine (PLL) polypeptide delivery platform designed to transport therapeutic molecules to gut cells and across the blood–brain barrier. Its lead product candidate, PLL001, is a first-in-class investigational therapy for Amyotrophic Lateral Sclerosis (ALS) targeting the gut–brain axis. The company also offers an early-stage, non-invasive blood biomarker diagnostic test for ALS with reported 92% sensitivity.

Is PLL Therapeutics a public or private company?

PLL Therapeutics is a private company. It is classified as management employee owned and is currently operating.

When was PLL Therapeutics founded?

PLL Therapeutics was founded in 2019. It employs 11 to 50 people.

Where is PLL Therapeutics based?

PLL Therapeutics is headquartered in Villenave-d'ornon, France, in the Europe region.

How does PLL Therapeutics make money?

Two revenue lines are on record. Pharmaceutical Development and Licensing is the primary driver. The others are diagnostic Services.

Does PLL Therapeutics have an API?

No public API is recorded for PLL Therapeutics.

What industry is PLL Therapeutics in?

PLL Therapeutics's product category is Neurology Biopharmaceuticals (ALS Therapeutics). Its primary akta.pro industry code is HLAAALAF, Companion Diagnostics (CDx) & Therapy Selection Assays, with a secondary code of HLAAAMAB, Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmiWeb.comPLL Therapeutics reports positive safety and tolerability results from phase I/II trial in ALS (Amyotrophic Lateral Sclerosis)PLL Therapeutics announced positive results from the first stage of its phase I/II clinical trial for PLL001 in 12 ALS patients, demonstrating favorable safety and tolerability with no serious adverse events reported. The study, conducted across multiple sites in Australia including Alfred Health, Calvary Health Care, and Wesley Research Institute, tested single ascending subcutaneous doses in a double-blind, placebo-controlled manner. The successful completion of this first-in-human trial clears the path for a larger phase II efficacy trial involving 140 patients in Australia and New Zealand, scheduled to begin in Q2 2026.PharmiWeb.comPLL Therapeutics opens subsidiary in New Zealand to accelerate ALS (Amyotrophic Lateral Sclerosis) treatment and early diagnostics breakthroughsPLL Therapeutics, a biopharmaceutical company based near Bordeaux, France, has opened a subsidiary in New Zealand to enroll 12 ALS patients in its Phase II clinical trial for drug candidate PLL001, building on successful Phase I results completed in Australia last month. New Zealand was chosen because its ALS incidence rate (~3 per 100,000) exceeds the global average (~2 per 100,000), and the subsidiary will partner with Pacific Clinical Research Network and New Zealand Clinical Research to accelerate trial implementation. The company, which is developing a polypeptide delivery platform targeting autoimmune and neurodegenerative diseases, expects Phase II to launch in early 2026 pending regulatory approvals.PharmiWeb.comPLL Therapeutics opens subsidiary in New Zealand to accelerate ALS (Amyotrophic Lateral Sclerosis) treatment and early diagnostics breakthroughsPLL Therapeutics, a French biopharmaceutical company, has opened a subsidiary in New Zealand to advance its phase II clinical trial for ALS treatment drug candidate PLL001, with the immediate goal of enrolling 12 patients at Pacific Clinical Research Network. The company successfully completed its phase I trial in Australia last month, showing the drug was safe and well-tolerated, and the phase II is scheduled to launch in early 2026 pending New Zealand Ethics Committee approval. New Zealand was chosen due to its higher-than-global-average ALS incidence rate and supportive regulatory environment, complementing the company's existing Australian subsidiary.